person · Reporting owner

WEATHERMAN ELIZABETH H

Disclosed activity across 6 companies

Tapewire entity: 40507
SEC CIK: 0001188681

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
INSULET CORPPODD · Entity 3516	Director	June 03, 2026	June 03, 2026
Royalty Pharma plcRPRX · Entity 3100	Director	June 05, 2026	June 08, 2026
VAPOTHERM INCVAPO · Entity 87270	Director	September 20, 2024	September 24, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INSULET CORP

Report date June 03, 2026 · Filed June 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,352	Reported balance After 2026-06-03 transaction · row 1 1 source row Row 1 · 2026-06-03 · Purchase · Acquired 3,450 · Balance 10,352 F1: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $143.21 to $145. Specifically: 1,607 shares were purchased in the range of $143.21 to $144.13, at a weighted average share price of $143.65; 1,843 shares were purchased in the range of $144.22 to $145, at a weighted average share price of $144.69. F2: Footnote continued: The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $143.21 to $145. Specifically: 1,607 shares were purchased in the range of $143.21 to $144.13, at a weighted average share price of $143.65; 1,843 shares were purchased in the range of $144.22 to $145, at a weighted average share price of $144.69.

F2: Footnote continued: The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.

Royalty Pharma plc

Report date June 05, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	Direct	13,103	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Grant · Acquired 4,545 · Balance 13,103 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

VAPOTHERM INC

Report date September 20, 2024 · Filed September 24, 2024

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-09-20 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2024-09-20 · Disposition to issuer · Disposed 14,555 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-09-20 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2024-09-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F2: The restricted stock unit awards, which these shares were subject to, were canceled in the merger in exchange for a cash payment of $2.18 per underlying share.
Common StockSEC Table I · non-derivative	IndirectElizabeth H. Weatherman Revocable Trust	Reported balance After 2024-09-20 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-09-20 · Disposition to issuer · Disposed 81,546 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $150.00 · Expires 2029-07-24	Direct	Reported balance After 2024-09-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-09-20 · Disposition to issuer · Disposed 1,187 · Balance 0 F3: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2020 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2032-07-27	Direct	Reported balance After 2024-09-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-09-20 · Disposition to issuer · Disposed 1,089 · Balance 0 F4: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2023 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share.

F2: The restricted stock unit awards, which these shares were subject to, were canceled in the merger in exchange for a cash payment of $2.18 per underlying share.

F3: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2020 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.

F4: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2023 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

NEVRO CORP

Report date April 03, 2025 · Filed April 03, 2025

Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-04-03 transaction · row 1 1 source row Row 1 · 2025-04-03 · Disposition to issuer · Disposed 86,171 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").

F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.

Silk Road Medical Inc

Report date September 17, 2024 · Filed September 19, 2024

Section 16 reporting ended · disclosed 2024-09-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-09-17 transaction · row 1 1 source row Row 1 · 2024-09-17 · Disposition to issuer · Disposed 155,004 · Balance 0 F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock. F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes. F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2026-08-04	Direct	Reported balance After 2024-09-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-09-17 · Disposition to issuer · Disposed 35,185 · Balance 0 F4: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $911,291.50, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2029-04-03	Direct	Reported balance After 2024-09-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-09-17 · Disposition to issuer · Disposed 8,910 · Balance 0 F5: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Filing footnotes · ownership attribution and instrument terms

F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.

F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.

F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.

F4: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $911,291.50, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

F5: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Wright Medical Group N.V.

Report date November 11, 2020 · Filed November 13, 2020

Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	Reported balance After 2020-11-11 transaction · row 1 1 source row Row 1 · 2020-11-11 · Other · Disposed 38,084 · Balance 0 F1: On November 4, 2019, Wright Medical Group N.V. (the Issuer) entered into a purchase agreement (the Purchase Agreement) with Stryker Corporation and its subsidiary, Stryker B.V. (the Purchaser). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share (Shares), of the Issuer (the Offer), and on November 11, 2020 (the Acceptance Time), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer, including 38,084 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the Offer Consideration), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.84 · Expires 2029-07-26	Direct	Reported balance After 2020-11-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-11 · Disposition to issuer · Disposed 11,691 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2028-07-24	Direct	Reported balance After 2020-11-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-11 · Disposition to issuer · Disposed 9,907 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.86 · Expires 2027-07-25	Direct	Reported balance After 2020-11-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-11 · Disposition to issuer · Disposed 10,275 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.24 · Expires 2026-07-19	Direct	Reported balance After 2020-11-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-11 · Disposition to issuer · Disposed 11,765 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: On November 4, 2019, Wright Medical Group N.V. (the Issuer) entered into a purchase agreement (the Purchase Agreement) with Stryker Corporation and its subsidiary, Stryker B.V. (the Purchaser). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share (Shares), of the Issuer (the Offer), and on November 11, 2020 (the Acceptance Time), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer, including 38,084 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the Offer Consideration), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).

F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 26, 2019 Filed Jul 30, 2019 17:20 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantStock Option (right to buy) · Derivative	11,691	$0.00 Strike: $27.84	$0.00	Disclosure SEC source: 0001235802-19-000087 · primary_doc.xml · derivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,691 Underlying: Ordinary Shares · 11,691 shares Expires 2029-07-26 Read SEC document
July 26, 2019 Filed Jul 30, 2019 17:20 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	3,357	$26.81	$90,001.17	Disclosure SEC source: 0001235802-19-000087 · primary_doc.xml · nonDerivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,084 F2 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan, in lieu of retainer fees in the aggregate amount of $90,000. F3 · balance_after: Includes 7,273 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
July 26, 2019 Filed Jul 30, 2019 17:20 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	3,916	$0.00	$0.00	Disclosure SEC source: 0001235802-19-000087 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,727 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
July 24, 2019 Filed Jul 25, 2019 21:47 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantOption to purchase Common Stock · Derivative	9,500	$0.00 Strike: $18.75	$0.00	Disclosure SEC source: 0001562180-19-004067 · primarydocument.xml · derivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2029-07-24 F1 · derivative.exercise_date: This option is eligible to vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2020 annual meeting of stockholders of the Company Read SEC document
July 17, 2019 Filed Jul 19, 2019 20:07 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantCommon Stock	773	$19.40	$14,996.20	Disclosure SEC source: 0001562180-19-004008 · primarydocument.xml · nonDerivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,101 F2 · shares: Compensation for services rendered during second quarter of 2019 in accordance with the company's non-employee director compensation plan and the company's equity plan. Read SEC document
June 07, 2019 Filed Jun 10, 2019 16:42 UTC	NEVRO CORP NVRO · Entity 12422	PurchaseCommon Stock	2,460	$60.99	$150,027.28	Disclosure SEC source: 0001567619-19-013162 · doc1.xml · nonDerivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,883 F4 · price: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $60.94 to $61.01, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 6,049 restricted stock units. Read SEC document
June 06, 2019 Filed Jun 10, 2019 16:42 UTC	NEVRO CORP NVRO · Entity 12422	PurchaseCommon Stock	4,128	$61.45	$253,677.16	Disclosure SEC source: 0001567619-19-013162 · doc1.xml · nonDerivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,423 F3 · price: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $61.31 to $61.79, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 6,049 restricted stock units. Read SEC document
June 06, 2019 Filed Jun 10, 2019 16:42 UTC	NEVRO CORP NVRO · Entity 12422	PurchaseCommon Stock	1,595	$60.99	$97,276.98	Disclosure SEC source: 0001567619-19-013162 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,295 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $60.31 to $61.18, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 6,049 restricted stock units. Read SEC document
June 05, 2019 Filed Jun 7, 2019 23:15 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantDirector Stock Option (Right to buy) · Derivative	2,612	$0.00 Strike: $46.15	$0.00	Disclosure SEC source: 0001209191-19-035660 · doc4.xml · derivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,612 Underlying: Common Stock · 2,612 shares Expires 2029-06-05 F1 · security: This option to purchase Common Stock was issued in replacement of the 2,400 share option reported as granted on April 3, 2019 pursuant to the Form 4 filed on April 5, 2019. A 2,400 share option was therefore not granted to the Reporting Person on April 3, 2019. F2 · derivative.exercise_date: One fourth of the shares subject to the option shall vest on each of September 1, 2019, December 1, 2019, March 1, 2020, and the date of the Issuer's 2020 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
May 20, 2019 Filed May 22, 2019 18:04 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	6,049	$0.00	$0.00	Disclosure SEC source: 0001567619-19-011873 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,700 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. RSUs shall vest in three (3) equal annual installments on each anniversary of March 19, 2019, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 6,049 RSUs. Read SEC document
April 12, 2019 Filed Apr 15, 2019 20:11 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantCommon Stock	778	$19.28	$14,999.84	Disclosure SEC source: 0001562180-19-002275 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,328 F1 · shares: Compensation for services rendered during first quarter of 2019 in accordance with the company's non-employee director compensation plan and the company's equity plan. Read SEC document
April 08, 2019 Filed Apr 10, 2019 23:03 UTC	Silk Road Medical Inc SILK · Entity 87417	ConversionSeries C Preferred Stock · Derivative	40,970	$0.00	$0.00	Disclosure SEC source: 0001628280-19-004135 · wf-form4_155493739518717.xml · derivative · entry 6 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,970 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document
April 08, 2019 Filed Apr 10, 2019 23:03 UTC	Silk Road Medical Inc SILK · Entity 87417	OtherSeries C Preferred Stock · Derivative	40,970	$0.00	$0.00	Disclosure SEC source: 0001628280-19-004135 · wf-form4_155493739518717.xml · derivative · entry 5 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,970 Underlying: Common Stock · 40,970 shares Expires not disclosed F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · kind: The Reporting Person paid cash to exercise this warrant to purchase shares of the Issuer's Series C Preferred Stock. F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document
April 08, 2019 Filed Apr 10, 2019 23:03 UTC	Silk Road Medical Inc SILK · Entity 87417	OtherSeries C Preferred Stock Warrant (Right to buy) · Derivative	40,970	$0.00 Strike: $6.11	$0.00	Disclosure SEC source: 0001628280-19-004135 · wf-form4_155493739518717.xml · derivative · entry 4 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,970 shares Expires 2023-10-13 F2 · kind: The Reporting Person paid cash to exercise this warrant to purchase shares of the Issuer's Series C Preferred Stock. F3 · derivative.exercise_date: All of the shares subject to the warrant are fully exercisable as of the date hereof. Read SEC document
April 08, 2019 Filed Apr 10, 2019 23:03 UTC	Silk Road Medical Inc SILK · Entity 87417	ConversionSeries C Preferred Stock · Derivative	163,880	$0.00	$0.00	Disclosure SEC source: 0001628280-19-004135 · wf-form4_155493739518717.xml · derivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 163,880 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document
April 08, 2019 Filed Apr 10, 2019 23:03 UTC	Silk Road Medical Inc SILK · Entity 87417	ConversionCommon Stock	40,970	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-19-004135 · wf-form4_155493739518717.xml · nonDerivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document
April 08, 2019 Filed Apr 10, 2019 23:03 UTC	Silk Road Medical Inc SILK · Entity 87417	ConversionCommon Stock	163,880	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-19-004135 · wf-form4_155493739518717.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document
April 04, 2019 Filed Apr 8, 2019 23:34 UTC	Silk Road Medical Inc SILK · Entity 87417	Exercise / conversionDirector Stock Option (Right to buy) · Derivative	174	$0.00 Strike: $8.27	$0.00	Disclosure SEC source: 0001628280-19-004031 · wf-form4_155476643393604.xml · derivative · entry 4 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 174 shares Expires 2026-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
April 04, 2019 Filed Apr 8, 2019 23:34 UTC	Silk Road Medical Inc SILK · Entity 87417	Exercise / conversionDirector Stock Option (Right to buy) · Derivative	70,370	$0.00 Strike: $1.60	$0.00	Disclosure SEC source: 0001628280-19-004031 · wf-form4_155476643393604.xml · derivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,185 Underlying: Common Stock · 70,370 shares Expires 2026-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, originally granted for 105,555 shares, of which 70,370 have been exercised, vests as to one forty-eighth of the shares on September 4, 2016 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
April 04, 2019 Filed Apr 8, 2019 23:34 UTC	Silk Road Medical Inc SILK · Entity 87417	Exercise / conversionCommon Stock	174	$8.27	$1,438.98	Disclosure SEC source: 0001628280-19-004031 · wf-form4_155476643393604.xml · nonDerivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 04, 2019 Filed Apr 8, 2019 23:34 UTC	Silk Road Medical Inc SILK · Entity 87417	Exercise / conversionCommon Stock	70,370	$1.60	$112,592.00	Disclosure SEC source: 0001628280-19-004031 · wf-form4_155476643393604.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 03, 2019 Filed Apr 6, 2019 01:35 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantDirector Stock Option (Right to buy) · Derivative	2,400	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0001628280-19-003994 · wf-form4_155451453890842.xml · derivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Common Stock · 2,400 shares Expires 2029-04-03 F2 · derivative.exercise_date: One fourth of the shares subject to the option shall vest on each of September 1, 2019, December 1, 2019, March 1, 2020, and the date of the Issuer's 2020 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
April 03, 2019 Filed Apr 6, 2019 01:35 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantDirector Stock Option (Right to buy) · Derivative	8,910	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0001628280-19-003994 · wf-form4_155451453890842.xml · derivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,910 Underlying: Common Stock · 8,910 shares Expires 2029-04-03 F1 · derivative.exercise_date: One third of the shares subject to the option shall vest on May 3, 2020 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
March 19, 2019 Filed Mar 21, 2019 20:38 UTC	NEVRO CORP NVRO · Entity 12422	GrantCommon Stock	651	$0.00	$0.00	Disclosure SEC source: 0001567619-19-007428 · doc1.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651 F1 · balance_after: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the next Annual Meeting of the Stockholders following March 19, 2019, subject to the Reporting Person's continued service to the issuer. Read SEC document
March 08, 2019 Filed Jul 19, 2019 20:07 UTC	VAPOTHERM INC VAPO · Entity 87270	OtherCommon Stock	37,316	$16.08	$600,041.28	Disclosure SEC source: 0001562180-19-004008 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Elizabeth H. Weatherman Revocable Trust Disclosed balance after: 37,316 F1 · balance_after: Reporting person acquired these shares through an investment made through an investment fund, which then transferred the shares to the Reporting person's trust on March 8, 2019. Read SEC document
February 01, 2019 Filed Feb 5, 2019 22:30 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantCommon Stock	390	$16.69	$6,509.10	Disclosure SEC source: 0001562180-19-000766 · primarydocument.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,550 F1 · shares: Compensation for services rendered during the fourth quarter of 2018 in accordance with the company's non employee director compensation plan and the company's equity plan. Read SEC document
November 19, 2018 Filed Nov 20, 2018 16:51 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionStock Option (right to buy) · Derivative	5,509	$0.00 Strike: $20.62	$0.00	Disclosure SEC source: 0001235802-18-000165 · primary_doc.xml · derivative · entry 6 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,509 shares Expires 2025-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option has fully vested. Read SEC document
November 19, 2018 Filed Nov 20, 2018 16:51 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionStock Option (right to buy) · Derivative	7,800	$0.00 Strike: $25.20	$0.00	Disclosure SEC source: 0001235802-18-000165 · primary_doc.xml · derivative · entry 5 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,800 shares Expires 2021-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option has fully vested. Read SEC document
November 19, 2018 Filed Nov 20, 2018 16:51 UTC	Wright Medical Group N.V. WMGI · Entity 145358	SaleOrdinary Shares, par value EUR 0.03 per share	2,640	$28.92	$76,339.56	Disclosure SEC source: 0001235802-18-000165 · primary_doc.xml · nonDerivative · entry 4 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,811 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $29.16, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F1 · balance_after: Includes 6,408 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document
November 19, 2018 Filed Nov 20, 2018 16:51 UTC	Wright Medical Group N.V. WMGI · Entity 145358	SaleOrdinary Shares, par value EUR 0.03 per share	13,309	$28.57	$380,260.76	Disclosure SEC source: 0001235802-18-000165 · primary_doc.xml · nonDerivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,451 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.42 to $28.76, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 6,408 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document
November 19, 2018 Filed Nov 20, 2018 16:51 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionOrdinary Shares, par value EUR 0.03 per share	5,509	$20.62	$113,595.58	Disclosure SEC source: 0001235802-18-000165 · primary_doc.xml · nonDerivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,408 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document
November 19, 2018 Filed Nov 20, 2018 16:51 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionOrdinary Shares, par value EUR 0.03 per share	7,800	$25.20	$196,560.00	Disclosure SEC source: 0001235802-18-000165 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,408 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. F2 · balance_after: Total holdings were increased by one ordinary share due to a rounding error in the Form 4 report that was filed with the SEC on July 26, 2018. Read SEC document
July 25, 2018 Filed Jul 26, 2018 21:36 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Tax withholdingOrdinary Shares, par value EUR 0.03 per share	626	$24.83	$15,543.58	Disclosure SEC source: 0001686266-18-000010 · primary_doc.xml · nonDerivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,450 F4 · balance_after: Includes 7,276 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document
July 24, 2018 Filed Jul 26, 2018 21:36 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantStock Option (right to buy) · Derivative	9,907	$0.00 Strike: $24.49	$0.00	Disclosure SEC source: 0001686266-18-000010 · primary_doc.xml · derivative · entry 4 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,907 Underlying: Ordinary Shares · 9,907 shares Expires 2028-07-24 F5 · derivative.exercise_date: This option vests in two annual installments, on the one-year and two-year anniversaries of July 24, 2018. Read SEC document
July 24, 2018 Filed Jul 26, 2018 21:36 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	3,472	$25.63	$88,987.36	Disclosure SEC source: 0001686266-18-000010 · primary_doc.xml · nonDerivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,076 F2 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan, in lieu of retainer fees in the aggregate amount of $89,000. F3 · balance_after: Includes 10,862 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document
July 24, 2018 Filed Jul 26, 2018 21:36 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	3,804	$0.00	$0.00	Disclosure SEC source: 0001686266-18-000010 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,604 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document
July 25, 2017 Filed Jul 26, 2017 17:17 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantStock Option (right to buy) · Derivative	10,275	$0.00 Strike: $27.86	$0.00	Disclosure SEC source: 0001235802-17-000123 · primary_doc.xml · derivative · entry 2 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,275 Underlying: Ordinary Shares · 10,275 shares Expires 2027-07-25 F3 · derivative.exercise_date: This option vests in two annual installments, on the one-year and two-year anniversaries of July 25, 2017. Read SEC document
July 25, 2017 Filed Jul 26, 2017 17:17 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	3,586	$0.00	$0.00	Disclosure SEC source: 0001235802-17-000123 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. F2 · balance_after: Includes 3,586 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document
July 19, 2017 Filed Jul 21, 2017 16:40 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Tax withholdingOrdinary Shares, par value EUR 0.03 per share	1,428	$27.58	$39,384.24	Disclosure SEC source: 0001235802-17-000113 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,214 Read SEC document
June 30, 2017 Filed Jul 5, 2017 16:02 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Tax withholdingOrdinary Shares, par value EUR 0.03 per share	173	$27.49	$4,755.77	Disclosure SEC source: 0001235802-17-000097 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,642 F1 · balance_after: Includes 4,094 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. Read SEC document
March 31, 2017 Filed Apr 3, 2017 16:19 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Tax withholdingOrdinary Shares, par value EUR 0.03 per share	202	$31.12	$6,286.24	Disclosure SEC source: 0001235802-17-000042 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,815 F1 · balance_after: Includes 5,041 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. Read SEC document
December 31, 2016 Filed Jan 3, 2017 16:44 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Tax withholdingOrdinary Shares, par value EUR 0.03 per share	344	$22.98	$7,905.12	Disclosure SEC source: 0001235802-17-000001 · primary_doc.xml · nonDerivative · entry 1 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,017 F1 · balance_after: Includes 5,988 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. Read SEC document
December 08, 2016 Filed Dec 9, 2016 18:38 UTC	Wright Medical Group N.V. WMGI · Entity 145358	SaleOrdinary Shares, par value EUR 0.03 per share	18,483	$24.09	$445,163.06	Disclosure SEC source: 0001686266-16-000006 · primary_doc.xml · nonDerivative · entry 6 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,361 F3 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.92 to $24.34 inclusive. The reporting person undertakes to provide to Wright Medical N.V., any security holder of Wright Medical N.V., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 6,935 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. Read SEC document
December 07, 2016 Filed Dec 9, 2016 18:38 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionStock Option (right to buy) · Derivative	5,509	$20.62 Strike: $20.62	$113,595.58	Disclosure SEC source: 0001686266-16-000006 · primary_doc.xml · derivative · entry 10 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,509 Underlying: Ordinary Shares · 5,509 shares Expires 2025-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option vests in two annual installments, on the one-year and two-year anniversaries of October 13, 2015. Read SEC document
December 07, 2016 Filed Dec 9, 2016 18:38 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionStock Option (right to buy) · Derivative	6,034	$21.66 Strike: $21.66	$130,696.44	Disclosure SEC source: 0001686266-16-000006 · primary_doc.xml · derivative · entry 9 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,034 shares Expires 2024-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option has fully vested. Read SEC document
December 07, 2016 Filed Dec 9, 2016 18:38 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionStock Option (right to buy) · Derivative	7,538	$19.45 Strike: $19.45	$146,614.10	Disclosure SEC source: 0001686266-16-000006 · primary_doc.xml · derivative · entry 8 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,538 shares Expires 2023-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option has fully vested. Read SEC document
December 07, 2016 Filed Dec 9, 2016 18:38 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionStock Option (right to buy) · Derivative	6,448	$18.04 Strike: $18.04	$116,321.92	Disclosure SEC source: 0001686266-16-000006 · primary_doc.xml · derivative · entry 7 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,448 shares Expires 2022-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option has fully vested. Read SEC document
December 07, 2016 Filed Dec 9, 2016 18:38 UTC	Wright Medical Group N.V. WMGI · Entity 145358	SaleOrdinary Shares, par value EUR 0.03 per share	25,529	$23.59	$602,303.14	Disclosure SEC source: 0001686266-16-000006 · primary_doc.xml · nonDerivative · entry 5 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,844 F2 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.26 to $23.76 inclusive. The reporting person undertakes to provide to Wright Medical N.V., any security holder of Wright Medical N.V., or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F1 · balance_after: Includes 6,935 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. Read SEC document
December 07, 2016 Filed Dec 9, 2016 18:38 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionOrdinary Shares, par value EUR 0.03 per share	5,509	$20.62	$113,595.58	Disclosure SEC source: 0001686266-16-000006 · primary_doc.xml · nonDerivative · entry 4 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,935 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. Read SEC document
December 07, 2016 Filed Dec 9, 2016 18:38 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionOrdinary Shares, par value EUR 0.03 per share	6,034	$21.66	$130,696.44	Disclosure SEC source: 0001686266-16-000006 · primary_doc.xml · nonDerivative · entry 3 WEATHERMAN ELIZABETH H · CIK 0001188681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,935 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.